{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:22:18Z","timestamp":1792624938920,"version":"4.5.0"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI103342"],"award-info":[{"award-number":["R01 AI103342"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0217439","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T17:31:36Z","timestamp":1560187896000},"page":"e0217439","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Vaccines targeting Staphylococcus aureus skin and bloodstream infections require different composition"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6718-4551","authenticated-orcid":true,"given":"Brian M.","family":"Luna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3366-7912","authenticated-orcid":true,"given":"Travis B.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Pantapalangkoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Boyle-Vavra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Bruhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Spellberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Daum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,6,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1001\/jama.298.15.1763","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections in the United States","volume":"298","author":"RM Klevens","year":"2007","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1086\/313710","article-title":"Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998","volume":"30","author":"AC Fluit","year":"2000","journal-title":"Clin Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"H Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0140-6736(06)68853-3","article-title":"Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat","volume":"368","author":"H Grundmann","year":"2006","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1128\/JCM.03221-14","article-title":"High Staphylococcus aureus colonization prevalence among patients with skin and soft tissue infections and controls in an urban emergency department","volume":"53","author":"N Kumar","year":"2015","journal-title":"J Clin Microbiol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJMcp070747","article-title":"Skin and Soft-Tissue Infections Caused by Methicillin-Resistant Staphylococcus aureus","volume":"357","author":"RS Daum","year":"2007","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.4049\/jimmunol.1600549","article-title":"Impact of Staphylococcus aureus USA300 Colonization and Skin Infections on Systemic Immune Responses in Humans","volume":"197","author":"M-L Alegre","year":"2016","journal-title":"J Immunol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.diagmicrobio.2013.02.020","article-title":"Microbiology of skin and soft tissue infections in the age of community-acquired methicillin-resistant Staphylococcus aureus","volume":"76","author":"GT Ray","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 1","key":"ref9","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.vaccine.2004.08.015","article-title":"A humanized monoclonal antibody targeting Staphylococcus aureus","volume":"22","author":"JM Patti","year":"2004","journal-title":"Vaccine"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1128\/AAC.00096-06","article-title":"Phase II, Randomized, Double-Blind, Multicenter Study Comparing the Safety and Pharmacokinetics of Tefibazumab to Placebo for Treatment of Staphylococcus aureus Bacteremia","volume":"50","author":"JJ Weems","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.4161\/hv.34407","article-title":"Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors","volume":"10","author":"TB McNeely","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1016\/j.vaccine.2016.03.110","article-title":"Status of vaccine research and development of vaccines for Staphylococcus aureus","volume":"34","author":"BK Giersing","year":"2016","journal-title":"Vaccine"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"16942","DOI":"10.1073\/pnas.0606863103","article-title":"Vaccine assembly from surface proteins of Staphylococcus aureus","volume":"103","author":"YK Stranger-Jones","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref14","unstructured":"Sagonowsky E. Pfizer cans $500M staph vaccine hopeful after phase 2b trial failure [Internet]. [cited 19 Feb 2019]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.fiercepharma.com\/vaccines\/pfizer-s-s-aureus-vaccine-faces-uncertain-future-after-phase-2b-trial-failure\" xlink:type=\"simple\">https:\/\/www.fiercepharma.com\/vaccines\/pfizer-s-s-aureus-vaccine-faces-uncertain-future-after-phase-2b-trial-failure<\/ext-link>"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"857","DOI":"10.4161\/hv.6.10.12469","article-title":"A new view on development of a Staphylococcus aureus vaccine: insights from mice and men","volume":"6","author":"B Spellberg","year":"2010","journal-title":"Hum Vaccin"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/cid\/cir828","article-title":"Progress toward a Staphylococcus aureus vaccine","volume":"54","author":"RS Daum","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00281-011-0293-5","article-title":"Development of a vaccine against Staphylococcus aureus","volume":"34","author":"B Spellberg","year":"2012","journal-title":"Semin Immunopathol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e29446","DOI":"10.1371\/journal.pone.0029446","article-title":"Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection","volume":"7","author":"G Luo","year":"2012","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1073\/pnas.1424924112","article-title":"Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus","volume":"112","author":"F Bagnoli","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0264-410X(02)00166-4","article-title":"Aluminum salts in vaccines\u2014US perspective","volume":"20","author":"NW Baylor","year":"2002","journal-title":"Vaccine"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nri3085","article-title":"Vaccines for the twenty-first century society","volume":"11","author":"R Rappuoli","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"ref22","unstructured":"CDC. Vaccine Excipient &amp; Media Summary [Internet]. 6 Jan 2017 [cited 1 Aug 2017]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/downloads\/appendices\/b\/excipient-table-2.pdf\" xlink:type=\"simple\">https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/downloads\/appendices\/b\/excipient-table-2.pdf<\/ext-link>"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1128\/IAI.00700-08","article-title":"The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus","volume":"76","author":"B Spellberg","year":"2008","journal-title":"Infect Immun"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1128\/IAI.55.4.843-847.1987","article-title":"Analysis by gel electrophoresis, Western blot, and peptide mapping of protein A heterogeneity in Staphylococcus aureus strains","volume":"55","author":"AL Cheung","year":"1987","journal-title":"Infect Immun"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1086\/509506","article-title":"Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?","volume":"194","author":"JM Voyich","year":"2006","journal-title":"J Infect Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1128\/IAI.00256-09","article-title":"The arginine catabolic mobile element is not associated with enhanced virulence in experimental invasive disease caused by the community-associated methicillin-resistant Staphylococcus aureus USA300 genetic background","volume":"77","author":"CP Montgomery","year":"2009","journal-title":"Infect Immun"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0217439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T03:50:42Z","timestamp":1608263442000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0217439"}},"subtitle":[],"editor":[{"given":"Paulo Lee","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,6,10]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0217439","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,10]]}}}